Preferred Primary Care Physicians

Pittsburgh, Pennsylvania 15317

1 studies enrolling now · 21 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Body Weight, COVID-19, Cardiovascular Disease, Diabetes Mellitus, Type 2, Dyslipidemia, Episodic Migraine, Headache, Migraine, Hypertension, Impaired Glucose Tolerance, Migraine, Migraine Disorders

Studies at this site

• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) — Recruiting now
• Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes — Paused
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention — Stopped early
• Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults — Completed
• Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine — Completed
• A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 — Stopped early
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone — Completed
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study — Completed
• A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults — Completed
• Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients — Stopped early
• To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies — Completed
• "Completeness of Response" Following Treatment With Treximet™ for Migraine — Completed